The Company’s breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.
Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Therma Bright received approval for the above claims from FDA (United States) in 1997.
ThermaBright Inc. trades on the TSX Venture Exchange (TSXV:THRM). Therma Bright Inc. holds patents pending and the trademarks for Therozap™ and the trademark InterceptCS™ along with with regulatory approvals for its thermal therapy technology.